Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1989 3
1990 1
1995 1
1996 1
1997 1
1998 1
1999 1
2000 1
2003 1
2005 1
2010 2
2011 3
2012 5
2013 3
2014 9
2015 4
2016 7
2017 3
2018 8
2019 11
2020 13
2021 17
2022 18
2023 25
2024 18

Text availability

Article attribute

Article type

Publication date

Search Results

137 results

Results by year

Filters applied: . Clear all
Page 1
Risk of virological failure after drug burden reduction in people with 4-class drug-resistant HIV on virological suppression: a retrospective cohort analysis of data from the PRESTIGIO Registry.
Clemente T, Diotallevi S, Lolatto R, Gagliardini R, Giacomelli A, Fiscon M, Ferrara M, Cervo A, Calza L, Maggiolo F, Rusconi S, Santoro MM, Castagna A, Spagnuolo V; PRESTIGIO Study Group. Clemente T, et al. Among authors: gagliardini r. Int J Antimicrob Agents. 2024 May 9:107195. doi: 10.1016/j.ijantimicag.2024.107195. Online ahead of print. Int J Antimicrob Agents. 2024. PMID: 38734216 No abstract available.
HIV-1 RNA monitoring with a dual-target diagnostic assay: A case report.
Sberna G, Gagliardini R, Rozera G, Forbici F, Cicalini S, Antinori A, Maggi F, Amendola A. Sberna G, et al. Among authors: gagliardini r. Heliyon. 2024 Apr 19;10(9):e29842. doi: 10.1016/j.heliyon.2024.e29842. eCollection 2024 May 15. Heliyon. 2024. PMID: 38699019 Free PMC article.
Human and Viral microRNA Expression in Acute and Chronic HIV Infections.
Lazzari E, Rozera G, Gagliardini R, Esvan R, Mondi A, Mazzotta V, Camici M, Girardi E, Antinori A, Maggi F, Abbate I. Lazzari E, et al. Among authors: gagliardini r. Viruses. 2024 Mar 23;16(4):496. doi: 10.3390/v16040496. Viruses. 2024. PMID: 38675839 Free PMC article.
SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV.
Vergori A, Cozzi-Lepri A, Tavelli A, Mazzotta V, Azzini AM, Gagliardini R, Mastrorosa I, Latini A, Pellicanò G, Taramasso L, Ceccherini-Silberstein F, Giannella M, Tacconelli E, Marchetti G, Monforte AD, Antinori A; Vax ICONA ORCHESTRA Study group. Vergori A, et al. Among authors: gagliardini r. Int J Infect Dis. 2024 Apr 19;144:107065. doi: 10.1016/j.ijid.2024.107065. Online ahead of print. Int J Infect Dis. 2024. PMID: 38643867 Free article.
Poor durability of the neutralizing response against XBB sublineages after a bivalent mRNA COVID-19 booster dose in persons with HIV.
Matusali G, Vergori A, Cimini E, Mariotti D, Mazzotta V, Lepri AC, Colavita F, Gagliardini R, Notari S, Meschi S, Fusto M, Tartaglia E, Girardi E, Maggi F, Antinori A; HIV‐VAC Study Group. Matusali G, et al. Among authors: gagliardini r. J Med Virol. 2024 Apr;96(4):e29598. doi: 10.1002/jmv.29598. J Med Virol. 2024. PMID: 38624044
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort.
d'Arminio Monforte A, Tavelli A, Di Biagio A, Sarmati L, Marchetti GC, Bai F, Cingolani A, Quiros Roldan E, Mussini C, Lichtner M, Vergori A, Piconi S, Orofino G, Fusco FM, Bandera A, Nozza S, Castagna A, Antinori A; ICONA Foundation Study Group. d'Arminio Monforte A, et al. J Antimicrob Chemother. 2024 Apr 6:dkae081. doi: 10.1093/jac/dkae081. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 38581349
Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options-the ICONA Foundation cohort study.
Lo Caputo S, Poliseno M, Tavelli A, Gagliardini R, Rusconi S, Lapadula G, Antinori A, Francisci D, Sarmati L, Gori A, Spagnuolo V, Ceccherini-Silberstein F, d'Arminio Monforte A, Cozzi-Lepri A; ICONA Foundation Study Group. Lo Caputo S, et al. Among authors: gagliardini r. Int J Infect Dis. 2024 Jun;143:106956. doi: 10.1016/j.ijid.2024.01.023. Epub 2024 Mar 5. Int J Infect Dis. 2024. PMID: 38447754 Free article.
Cohort profile: PRESTIGIO, an Italian prospective registry-based cohort of people with HIV-1 resistant to reverse transcriptase, protease and integrase inhibitors.
Clemente T, Galli L, Lolatto R, Gagliardini R, Lagi F, Ferrara M, Cattelan AM, Focà E, Di Biagio A, Cervo A, Calza L, Maggiolo F, Marchetti G, Cenderello G, Rusconi S, Zazzi M, Santoro MM, Spagnuolo V, Castagna A; PRESTIGIO Study Group. Clemente T, et al. Among authors: gagliardini r. BMJ Open. 2024 Feb 10;14(2):e080606. doi: 10.1136/bmjopen-2023-080606. BMJ Open. 2024. PMID: 38341206 Free PMC article.
Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort.
Gagliardini R, Giacomelli A, Bozzi G, D'Arminio Monforte A, Tavelli A, Mazzotta V, Bruzzesi E, Cervo A, Saracino A, Mussini C, Girardi E, Cozzi-Lepri A, Antinori A; ICONA Foundation study group. Gagliardini R, et al. Travel Med Infect Dis. 2024 Mar-Apr;58:102691. doi: 10.1016/j.tmaid.2024.102691. Epub 2024 Feb 8. Travel Med Infect Dis. 2024. PMID: 38336335 Free article.
137 results